At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Pre-Mkt 04-10 04:15:03 EDT
9.29
-0.16
-1.69%
High9.56Low9.20Vol510.76K
Open9.28D1 Closing9.45Amplitude3.86%
Mkt Cap290.68MTradable Cap145.78MTotal Shares31.29M
T/O4.75MT/O Rate3.25%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership
Simply Wall St.  ·  12:55
Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership
PharmaEssentia to Buy Forus Therapeutics for C$50 Million
MT Newswires Live  ·  12:52
PharmaEssentia to Buy Forus Therapeutics for C$50 Million
Arovella Therapeutics Seeks ASX Quotation for 1.6 Million New Shares
TIPRANKS  ·  12:37
Arovella Therapeutics Seeks ASX Quotation for 1.6 Million New Shares
AN2 Therapeutics Files $300 Million Mixed Shelf
MT Newswires Live  ·  05:50
AN2 Therapeutics Files $300 Million Mixed Shelf
AN2 Therapeutics Launches New $80 Million ATM Program
TIPRANKS  ·  05:34
AN2 Therapeutics Launches New $80 Million ATM Program
AN2 Therapeutics files $300M mixed securities shelf
TIPRANKS  ·  05:25
AN2 Therapeutics files $300M mixed securities shelf
Galera Therapeutics Announces Share Conversions and Warrant Exercise
TIPRANKS  ·  04:40
Galera Therapeutics Announces Share Conversions and Warrant Exercise
enGene Therapeutics Rebrands as Company Nears Commercialization
TIPRANKS  ·  04:38
enGene Therapeutics Rebrands as Company Nears Commercialization
Dianthus Therapeutics Initiated at Outperform by Wolfe Research
Dow Jones  ·  00:45
Dianthus Therapeutics Initiated at Outperform by Wolfe Research
Quince Therapeutics Announces 1-for-10 Reverse Stock Split
TIPRANKS  ·  04-09 22:17
Quince Therapeutics Announces 1-for-10 Reverse Stock Split
C4 Therapeutics and Roche Expand Partnership with New $1 Billion-Plus Cancer Drug Deal
Deep News  ·  04-09 22:10
C4 Therapeutics and Roche Expand Partnership with New $1 Billion-Plus Cancer Drug Deal
Oruka Therapeutics Price Target Maintained With a $125.00/Share by Guggenheim
Dow Jones  ·  04-09 22:01
Oruka Therapeutics Price Target Maintained With a $125.00/Share by Guggenheim
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
GlobeNewswire  ·  04-09 20:50
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases
GlobeNewswire  ·  04-09 20:00
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases
Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
TIPRANKS  ·  04-09 19:37
Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
Press Release: Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
Dow Jones  ·  04-09 19:30
Press Release: Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
GlobeNewswire  ·  04-09 19:00
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
Ovid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy Rating
TIPRANKS  ·  04-09 18:15
Ovid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy Rating
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
TIPRANKS  ·  04-09 18:10
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
Huachuang Securities Reaffirms Their Buy Rating on Qyuns Therapeutics Co., Ltd. Class H (2509)
TIPRANKS  ·  04-09 16:39
Huachuang Securities Reaffirms Their Buy Rating on Qyuns Therapeutics Co., Ltd. Class H (2509)

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--